Literature DB >> 26780999

Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.

Michael J Zelefsky1, Bing Ying Poon2, James Eastham3, Andrew Vickers2, Xin Pei4, Peter T Scardino3.   

Abstract

PURPOSE: We evaluated quality-of-life changes (QoL) in 907 patients treated with either radical prostatectomy (open or laparoscopic), real-time planned conformal brachytherapy, or high-dose intensity-modulated radiotherapy (IMRT) on a prospective IRB-approved longitudinal study.
METHODS: Validated questionnaires given pretreatment (baseline) and at 3, 6, 9, 12, 15, 18, 24, 36, and 48 months addressed urinary function, urinary bother, bowel function, bowel bother, sexual function, and sexual bother.
RESULTS: At 48 months, surgery had significantly higher urinary incontinence than others (both P<.001), but fewer urinary irritation/obstruction symptoms (all P<.001). Very low levels of bowel dysfunction were observed and only small subsets in each group showed rectal bleeding. Brachytherapy and IMRT showed better sexual function than surgery accounting for baseline function and other factors (delta 14.29 of 100, 95% CI, 8.57-20.01; and delta 10.5, 95% CI, 3.78-17.88). Sexual bother was similar. Four-year outcomes showed persistent urinary incontinence for surgery with more obstructive urinary symptoms for radiotherapy. Using modern radiotherapy delivery, bowel function deterioration is less-often observed. Sexual function was strongly affected in all groups yet significantly less for radiotherapy.
CONCLUSIONS: Treatment selection should include patient preferences and balance predicted disease-free survival over a projected time vs potential impairment of QoL important for the patient.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Prostate cancer; Quality of life; Radiotherapy; Surgery

Mesh:

Year:  2016        PMID: 26780999      PMCID: PMC4848377          DOI: 10.1016/j.radonc.2015.11.035

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.

Authors:  Yolanda Pardo; Ferran Guedea; Ferrán Aguiló; Pablo Fernández; Víctor Macías; Alfonso Mariño; Asunción Hervás; Ismael Herruzo; María José Ortiz; Javier Ponce de León; Jordi Craven-Bratle; José Francisco Suárez; Ana Boladeras; Àngels Pont; Adriana Ayala; Gemma Sancho; Evelyn Martínez; Jordi Alonso; Montserrat Ferrer
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Physician visits prior to treatment for clinically localized prostate cancer.

Authors:  Thomas L Jang; Justin E Bekelman; Yihai Liu; Peter B Bach; Ethan M Basch; Elena B Elkin; Michael J Zelefsky; Peter T Scardino; Colin B Begg; Deborah Schrag
Journal:  Arch Intern Med       Date:  2010-03-08

3.  Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.

Authors:  David C Miller; Martin G Sanda; Rodney L Dunn; James E Montie; Hector Pimentel; Howard M Sandler; William P McLaughlin; John T Wei
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer.

Authors:  Ida J Korfage; Marie-Louise Essink-Bot; Gerard J J M Borsboom; Joanna B Madalinska; Wim J Kirkels; J Dik F Habbema; Fritz H Schröder; Harry J de Koning
Journal:  Int J Cancer       Date:  2005-08-20       Impact factor: 7.396

5.  A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development.

Authors:  Christie A Befort; Michael J Zelefsky; Peter T Scardino; Evelinn Borrayo; R Brian Giesler; Michael W Kattan
Journal:  Clin Prostate Cancer       Date:  2005-09

6.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.

Authors:  Pirus Ghadjar; Andrew Jackson; Daniel E Spratt; Jung Hun Oh; Per Munck af Rosenschöld; Marisa Kollmeier; Ellen Yorke; Margie Hunt; Joseph O Deasy; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-02-14       Impact factor: 20.096

8.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

9.  Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.

Authors:  Mark S Litwin; John L Gore; Lorna Kwan; Judson M Brandeis; Steve P Lee; H Rodney Withers; Robert E Reiter
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

10.  An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.

Authors:  Steven J Frank; Louis L Pisters; John Davis; Andrew K Lee; Roland Bassett; Deborah A Kuban
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more
  11 in total

1.  125I brachytherapy in younger prostate cancer patients : Outcomes in low- and intermediate-risk disease.

Authors:  Isabelle Kindts; Karin Stellamans; Ignace Billiet; Hans Pottel; Antoon Lambrecht
Journal:  Strahlenther Onkol       Date:  2017-05-09       Impact factor: 3.621

2.  Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Authors:  Daniel A Barocas; JoAnn Alvarez; Matthew J Resnick; Tatsuki Koyama; Karen E Hoffman; Mark D Tyson; Ralph Conwill; Dan McCollum; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Sherrie H Kaplan; Lisa E Paddock; Antoinette M Stroup; Xiao-Cheng Wu; David F Penson
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

3.  Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor
Journal:  Acta Oncol       Date:  2017-09-08       Impact factor: 4.089

4.  Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Authors:  Karen E Hoffman; David F Penson; Zhiguo Zhao; Li-Ching Huang; Ralph Conwill; Aaron A Laviana; Daniel D Joyce; Amy N Luckenbaugh; Michael Goodman; Ann S Hamilton; Xiao-Cheng Wu; Lisa E Paddock; Antoinette Stroup; Matthew R Cooperberg; Mia Hashibe; Brock B O'Neil; Sherrie H Kaplan; Sheldon Greenfield; Tatsuki Koyama; Daniel A Barocas
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

Review 5.  Low dose rate prostate brachytherapy.

Authors:  Bradley J Stish; Brian J Davis; Lance A Mynderse; Robert H McLaren; Christopher L Deufel; Richard Choo
Journal:  Transl Androl Urol       Date:  2018-06

6.  Understanding Medical Decision-making in Prostate Cancer Care.

Authors:  Rachel Thera; Dr Tracey Carr; Dr Gary Groot; Nicole Baba; Dr Kunal Jana
Journal:  Am J Mens Health       Date:  2018-06-07

7.  Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP).

Authors:  Chiara Marzorati; Dario Monzani; Ketti Mazzocco; Francesca Pavan; Gabriele Cozzi; Ottavio De Cobelli; Massimo Monturano; Gabriella Pravettoni
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

8.  Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.

Authors:  Joanne W Jang; Michael R Drumm; Jason A Efstathiou; Jonathan J Paly; Andrzej Niemierko; Marek Ancukiewicz; James A Talcott; Jack A Clark; Anthony L Zietman
Journal:  Cancer Med       Date:  2017-05-31       Impact factor: 4.452

9.  Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.

Authors:  Aurore Goineau; Loïc Campion; Bénédicte d'Aillières; Brigitte Vié; Agnès Ghesquière; Guillaume Béra; Didier Jaffres; Guy de Laroche; Nicolas Magné; Xavier Artignan; Jérôme Chamois; Philippe Bergerot; Etienne Martin; Gilles Créhange; Elisabeth Deniaud-Alexandre; Xavier Buthaud; Yazid Belkacémi; Mélanie Doré; Laure de Decker; Stéphane Supiot
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

10.  Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.

Authors:  Nadine Houédé; Xavier Rébillard; Sophie Bouvet; Sarah Kabani; Pascale Fabbro-Peray; Brigitte Trétarre; Florence Ménégaux
Journal:  BMC Cancer       Date:  2020-08-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.